Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 317-323

  Safarika, A ^a   Galani, I ^a   Pistiki, A ^a   Giamarellos Bourboulis, E J ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; IMIPENEM; LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CLINICAL ARTICLE; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER INFECTIONS; COMBINATION DRUG THERAPY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS INFECTIONS; TIME FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMIPENEM; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 84921762270     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2231-7     Document Type: Article

References (23)

1. Fischbach MA (2011) Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 14:519–523
2. Shorr AF, Zadeikis N, Jackson WL, Ramage AS, Wu SC, Tennenberg AM, Kollef MH (2005) Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 40(Suppl 2):S123–S129
3. Benko R, Matuz M, Doro P, Peto Z, Molnar A, Hajdu E, Nagy E, Gardi J, Soos G (2007) Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. Int J Antimicrob Agents 30:162–168
4. Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M (2003) Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 42:589–598
5. Hutschala D, Skhirtladze K, Zuckermann A, Wisser W, Jaksch P, Mayer-Helm BX, Burgmann H, Wolner E, Müller M, Tschernko EM (2005) In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chemother 49:5107–5111
6. Conte JE Jr, Golden JA, McIver M, Little E, Zurlinden E (2007) Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents 30:422–427
7. Conte JE Jr, Golden JA, McIver M, Zurlinden E (2006) Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 28:114–121
8. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas V, Kotanidou A, Roussos C, Giamarellou H (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46:1157–1164
9. Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, Adamis S, Alexiou Z, Andrianopoulos G, Antonopoulou A, Athanassia S, Baziaka F, Charalambous A, Christodoulou S, Dimopoulou I, Floros I, Giannitsioti E, Gkanas P, Ioakeimidou A, Kanellakopoulou K, Karabela N, Karagianni V, Katsarolis I, Kontopithari G, Kopterides P, Koutelidakis I, Koutoukas P, Kranidioti H, Lignos M, Louis K, Lymberopoulou K, Mainas E, Marioli A, Massouras C, Mavrou I, Mpalla M, Michalia M, Mylona H, Mytas V, Papanikolaou I, Papanikolaou K, Patrani M, Perdios I, Plachouras D, Pistiki A, Protopapas K, Rigaki K, Sakka V, Sartzi M, Skouras V, Souli M, Spyridaki A, Strouvalis I, Tsaganos T, Zografos G, Mandragos K, Klouva-Molyvdas P, Maggina N, Giamarellou H, Armaganidis A, Giamarellos-Bourboulis EJ (2010) Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 14:R96
10. Rodvold KA, Danziger LH, Gotfried MH (2003) Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 47:2450–2457
11. Adamis G, Papaioannou MG, Giamarellos-Bourboulis EJ, Gargalianos P, Kosmidis J, Giamarellou H (2004) Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. Int J Antimicrob Agents 23:144–149
12. Li C, Nicolau DP, Lister PD, Quintiliani R, Nightingale CH (2004) Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. J Antimicrob Chemother 53:297–304
13. Drusano GL, Lodise TP, Melnick D, Liu W, Oliver A, Mena A, VanScoy B, Louie A (2011) Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrob Agents Chemother 55:3406–3412
14. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, Douglas A, Lipman J (2005) Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:4814–4815
15. Athanassa ZE, Markantonis SL, Fousteri MZF, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ (2012) Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38:1779–1786
16. Giamarellos-Bourboulis EJ, Kentepozidis N, Antonopoulou A, Plachouras D, Tsaganos T, Giamarellou H (2005) Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 51:113–117
17. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ; Canadian Antimicrobial Resistance Alliance (2008) Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 62:67–80
18. Kresken M, Körber-Irrgang B, Läuffer J, Decker-Burgard S, Davies T (2011) In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time–kill assay methodology. Int J Antimicrob Agents 38:70–75
19. Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL (2010) The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 54:2646–2654
20. Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL (2009) Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrob Agents Chemother 53:3325–3330
21. Bassetti M, Righi E, Rosso R, Mannelli S, Di Biagio A, Fasce R, Pallavicini FB, Marchetti F, Viscoli C (2006) Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit. Int J Antimicrob Agents 28:582–585
22. Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, Nikolaou M, Quinn JP, Prince RA, Tam VH (2008) Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 52:2898–2904
23. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM (2012) Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10:917–934